Jun 30 2010

Cato at the 12th World Congress on Gastrointestinal Cancer

Cato Research will be attending the European Society for Medical Oncology‘s (ESMO)  12th World Congress on Gastrointestinal Cancer in Barcelona, Spain from 30 June to 03 July 2010.  ESMO is the leading European professional organization representing medical oncologists.  The conference will focus on personalized therapy, multidisciplinary management and unraveling molecular mechanisms related to malignancies affecting every component of the gastrointestinal tract.  Presentation of research is one of the highlights of the conference, with more than 400 abstracts accepted for presentation and publication in a special supplement to the Annals of Oncology in 2009.

Lynda Sutton, Chief Operating Officer and Chief Regulatory Officer of Cato Research and President of Cancer Advances will be presenting data from Cancer Advances’ clinical trials in colorectal cancer.  The poster is titled, “Inhibition of gastrin supports mechanism based efficacy in colorectal cancer.”  Preclinical studies in animal models have shown that blocking gastrin with endogenously induced or applied anti-G17 antibodies reduces the growth rate and metastatic spread of gastric adenocarcinomas.  The company’s lead compound, PAS or Polyclonal Antibody Stimulator, functions by stimulating the immune system in the recipient to produce endogenous polyclonal antibodies to gastrin.  In these clinical trials, Cancer Advances demonstrated for the first time in a clinical setting that blocking gastrin with use of autologous antibodies to G17 reduces free gastrin levels and improves clinical efficacy.  This mechanism based efficacy measure of PAS strongly supports predictions of clinical benefit in patients who mount an immune response.  Moreover, responders had a significantly prolonged survival rate compared to nonresponders.  This survival benefit, together with the highly favorable safety profile, indicates that PAS has exciting prospects as a component of an improved anti cancer treatment regimen for colorectal cancer.